Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2023-11-28 Share Issue/Capital Cha…
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - IVX 9 pages 33.1KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of Issue, Conversion or Payment up of Unquoted Equity Securities' and details the issuance of unquoted options under an employee incentive scheme by Invion Limited. It includes specifics such as the number of securities issued, issue date, security descriptions, and references to ASX listing rules. The content is focused on the announcement of new securities issued, not a financial report or audit. It is a regulatory announcement about securities issuance, fitting the category of Share Issue/Capital Change (SHA). The document length is 7540 characters, which is substantive and contains detailed issuance information, not just a brief notice or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is SHA with high confidence.
2023-11-28 English
Major Milestone towards Clinical Trials 2 pages 234.6KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement from Invion Limited about achieving a major milestone in manufacturing their lead drug candidate under GMP standards, preparing for upcoming Phase 1 clinical trials. It is a corporate update on progress towards clinical trials and manufacturing capabilities, not a financial report, earnings release, or regulatory filing. The content focuses on operational progress and partnership details rather than financial results or governance changes. The document length is 4426 characters, which is relatively short and typical for an announcement. It does not contain financial statements or detailed financial data, nor does it announce voting results, capital changes, or legal proceedings. Therefore, the best fitting category is Capital/Financing Update (CAP) as it relates to progress in drug manufacturing and readiness for clinical trials, which is a form of operational and capital milestone update relevant to investors.
2023-11-20 English
Notice of Annual General Meeting/Proxy Form 15 pages 793.9KB
AGM Information Classification · 100% confidence The document is a detailed notice of the Annual General Meeting (AGM) for Invion Limited, including the date, time, virtual meeting details, agenda items, resolutions to be voted on, proxy information, and voting instructions. It references the financial period ended 30 June 2023 and mentions the receipt and consideration of accounts and reports, including the Remuneration Report. The document is clearly a Notice of Meeting and related explanatory materials for the AGM, not the actual Annual Report or financial statements themselves. It is a communication to shareholders about the upcoming AGM and how to participate, vote, and submit proxies. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM. The document is lengthy (15,000 characters) and contains substantive AGM-related content, not just a brief announcement or link to a report, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is AGM Information (AGM-R).
2023-10-29 English
Notification of cessation of securities - IVX 5 pages 25.2KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the expiry of options (convertible securities) for Invion Limited. It provides specific information about the securities that have ceased, the reason for cessation (expiry without exercise or conversion), and the updated issued capital following these changes. The document is a regulatory announcement about changes in the company's issued securities, specifically the cessation of certain options. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but an announcement of a capital change event related to securities. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is 4546 characters, which is consistent with an announcement rather than a full report.
2023-10-29 English
Activities Report and Appendix 4C 8 pages 245.4KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement titled 'Activity Report and Cash Flow Report for the Quarter Ended 30 September 2023'. It includes detailed financial data such as cash flow statements, operating cash flows, investing and financing activities, and cash position summaries for the quarter. The presence of an Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed entities, confirms this is a quarterly financial report. The document contains substantive financial data and analysis for a period shorter than a full fiscal year (the quarter ended 30 September 2023). Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report or a certification, but a full quarterly financial report with detailed financial statements and commentary. Q1 2024
2023-10-23 English
Investor Presentation 18 pages 11.1MB
Regulatory Filings
2023-10-23 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.